With over 200 biopharma/biotech companies operating in Belgium (8-10% of all such companies in Europe), the Belgian biopharma/biotech companies account for 16% of Europe’s turnover and almost 10% of R&D expenditure.
Universities played and are playing a key role in technology transfer with strong collaboration between their various departments resulting in intensive exchanges of knowledge and ultimately driving further development in the sector. Spin-off biopharma/biotech companies are springing up all over Belgium with all regions (Flanders, Wallonia and Brussels) very active in the sector.

But what is next?
What kind of development can we expect from the sector in the next 10 years?

Be IQVIA's guest at their offices in Belgium (Zaventem) on Friday, the 26th of October for a program featuring a sneak preview at thoughts gathered by Roularta Healthcare through in-depth interviews with key sector stakeholders. The results will later be published in a special edition of the Journal du Médecin/De Artsenkrant.

The research focusses on

  • Insights of CEOs from biopharma/biotech companies on market valuation, financing, navigating regulatory hurdles, and successful commercialization. 
  • The Belgian Minister of Health’s policy priorities and vision for the sector’s future. 
  • The perspective of leaders in BioWin, FlandersBio, and VIB on where the sector will be in 10 years. 

Please mark your calendar for the 26th of October and plan to join us for this informative and interesting program, including lunch.
The session will begin at 10:30 and will conclude at 14:00 (a detailed agenda with speakers will follow)